Department of Gastroenterological Surgery, Minoh City Hospital, Minoh, Japan.
Department of Surgery, Toyonaka Municipal Hospital, 4-14-1, Shibahara-cho, Toyonaka, Osaka, 560-8565, Japan.
J Gastrointest Surg. 2022 Jan;26(1):128-140. doi: 10.1007/s11605-021-05070-6. Epub 2021 Jul 13.
Due to its rarity and biological heterogeneity, guidelines for primary appendiceal tumor (PAT) are based on scarce evidence, resulting in no strong recommendations. The present study explored prognosis-related factors, including the timing of lymph node dissection (LND), in PAT patients after curative resection (CR) to determine the optimal surgical therapies.
We retrospectively collected and analyzed data from 404 patients with PATs who underwent CR at 43 tertiary hospitals from 2000 to 2017. This manuscript is based on revised manuscript during review process. Please, change the bold characters to normal characters in the manuscript.
After propensity score matching, there were no marked differences in the recurrence-free survival (RFS) or overall survival (OS) between the primary and secondary LND groups (P = 0.993 and 0.728). A multivariate analysis showed that lymph node metastasis (LNM) was an independent factor for the RFS (hazard ratio [HR] 2.59; 95% confidence interval [CI] 1.09-6.13; P = 0.031) and OS (HR 4.70; 95% CI 1.40-15.76; P = 0.012). There were significant associations between the LNM rates and tumor depth (P < 0.0001) and the histological type (P = 0.006). There was no LNM in patients with low-grade appendiceal mucinous neoplasm (LAMN) or well-differentiated mucinous adenocarcinoma (G1) or patients with any Tis or T1 PATs.
LNM was an independent prognostic predictor in PATs after CR with LND. Tumor depth and histological type were not prognostic predictors but were LNM predictors. Secondary LND based on the pathological findings of resected specimens is considered an acceptable surgical management without a worse prognosis than primary LND, and it may be omitted in LAMN+G1 or in any Tis and T1 PATs.
由于原发性阑尾肿瘤(PAT)的罕见性和生物学异质性,基于有限证据制定的指南并未提供强有力的推荐意见。本研究旨在探讨影响 PAT 患者根治性切除(CR)后预后的相关因素,包括淋巴结清扫术(LND)的时机,以确定最佳的手术治疗策略。
我们回顾性收集了 2000 年至 2017 年期间在 43 家三级医院接受 CR 治疗的 404 例 PAT 患者的数据,并进行了分析。本文基于审稿过程中的修订稿。请将手稿中的粗体字改为正常字体。
在进行倾向评分匹配后,原发和继发 LND 组之间的无复发生存率(RFS)或总生存率(OS)无显著差异(P=0.993 和 0.728)。多因素分析显示,淋巴结转移(LNM)是 RFS(风险比[HR]2.59;95%置信区间[CI]1.09-6.13;P=0.031)和 OS(HR 4.70;95%CI 1.40-15.76;P=0.012)的独立预后因素。LNM 率与肿瘤深度(P<0.0001)和组织学类型(P=0.006)显著相关。在低级别阑尾黏液性肿瘤(LAMN)或高分化黏液性腺癌(G1)或任何Tis 或 T1PAT 患者中,均未发现 LNM。
LNM 是 CR 后行 LND 的 PAT 患者的独立预后预测因素。肿瘤深度和组织学类型不是预后预测因素,但与 LNM 相关。基于切除标本的病理发现行继发性 LND 被认为是一种可接受的手术管理方式,其预后并不比原发性 LND 差,对于 LAMN+G1 或任何Tis 和 T1PAT 患者,可能可以省略 LND。